Trump Fast-Tracks Psychedelic Review for Mental Health Treatments

President Trump signs an executive order to fast track the review of psilocybin and ibogaine as potential treatments for mental health conditions. The move aims to accelerate research into these psychedelic substances.

President Trump has signed an executive order that will expedite the review process for using psychedelics like psilocybin and ibogaine as potential treatments for mental health disorders. The move aims to accelerate research into the therapeutic potential of these mind-altering substances, which have shown promising results in clinical trials for conditions like depression, anxiety, and PTSD.

In a surprise move, Trump reportedly requested access to the psychedelics himself, stating

Trump Expedites Review of Psychedelics for Mental Health Disorders

Comments (0)

Related Articles

Potential Contamination Sparks HiPP Baby Food Recall in Austria

Deadly Fentanyl Epidemic Persists: Experts Warn US Struggles to Respond

New Treatments Accelerate for Serious Mental Illness